LOW INFLIXIMAB TROUGH LEVELS AT WEEK 6 AND 14 IN AN ASIAN INFLAMMATORY BOWEL DISEASE COHORT ARE NOT ASSOCIATED WITH POORER CLINICAL OUTCOME

被引：0
|
作者：
Lim, Chong Teik
Koh, Samantha J.
Tay, Shu Wen
Salazar, Ennaliza
Chan, Pak Wo
Tan, Malcolm
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP1307
引用
下载
收藏
页码：S1095 / S1096
页数：2
相关论文
共 50 条
  • [1] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [2] Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (11): : 1316 - 1325
  • [3] Infliximab trough levels are associated with disease activity in pediatric inflammatory bowel disease
    Hoekman, D. R.
    Brandse, J. F.
    de Meij, T. G.
    Hummel, T. Z.
    Lowenberg, M.
    Benninga, M. A.
    D'Haens, G. R. A. M.
    Kindermann, A.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S412 - S412
  • [4] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, J.
    Sever, N.
    Ferkolj, I.
    Stabuc, B.
    Smrekar, N.
    Kozelj, M.
    Novak, G.
    Gils, A.
    Drobne, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
  • [5] VEDOLIZUMAB TROUGH LEVELS AT WEEK 6 PREDICT ENDOSCOPIC AND CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kozelj, Matic
    Novak, Gregor
    Gils, Ann
    Drobne, David
    GASTROENTEROLOGY, 2018, 154 (06) : S819 - S819
  • [6] Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease
    Vaughan, Rose
    Murphy, Elise
    Nalder, Michelle
    Gibson, Robert N.
    Ardalan, Zaid
    Boussioutas, Alex
    Christensen, Britt
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (07) : 1080 - 1088
  • [7] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
    Merras-Salmio, Laura
    Kolho, Kaija-Leena
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278
  • [8] Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease
    Courbette, Olivier
    Aupiais, Camille
    Viala, Jerome
    Hugot, Jean-Pierre
    Roblin, Xavier
    Candon, Sophie
    Louveau, Baptiste
    Chatenoud, Lucienne
    Martinez-Vinson, Christine
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 310 - 317
  • [9] ANTIBODIES TO INFLIXIMAB AND INFLIXIMAB TROUGH LEVELS IN THE MANAGEMENT OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Dilillo, A.
    Isoldi, S.
    Mallardo, S.
    Civitelli, F.
    Oliva, S.
    Aloi, M.
    Rossi, P.
    Carbogno, S.
    Viola, F.
    Cucchiara, S.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E271 - E271
  • [10] Large Variation in Infliximab Trough Levels Is Associated With Disease Activity in Paediatric Inflammatory Bowel Disease
    Hoekman, Danil R.
    Brandse, Johannan F.
    de Meij, Tim
    Hummel, Thalia
    Lowenberg, M.
    Benninga, Marc A.
    D'Haens, Geert R.
    Kindermann, Angelika
    GASTROENTEROLOGY, 2014, 146 (05) : S782 - S782
12345